Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TKM PLK1

Next Previous
X
Search
Drug Profile

TKM PLK1

Alternative Names: PLK-1SNALP; PLK1-LNP; TKM-080301; TKM-PLK1

Latest Information Update: 02 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Alnylam Pharmaceuticals; Tekmira Pharmaceuticals Corporation
  • Developer Arbutus Biopharma
  • Class Antineoplastics; Small interfering RNA
  • Mechanism of Action Polo-like kinase 1 inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Suspended Adrenocortical carcinoma; Liver cancer; Lymphoma; Neuroendocrine tumours; Solid tumours

Most Recent Events

  • 21 Mar 2017 Suspended - Phase-I for Lymphoma (Second-line therapy or greater) in USA (IV) due to company focusing its efforts on its HBV assets (Arbutus 10-K filed in 2017)
  • 21 Mar 2017 Suspended - Phase-I for Solid tumours (Late-stage disease, Second-line therapy or greater) in USA (IV) due to company focusing its efforts on its HBV assets (Arbutus 10-K filed in 2017)
  • 21 Mar 2017 Suspended - Phase-I/II for Adrenocortical carcinoma (Second-line therapy or greater) in USA (IV) due to company focusing its efforts on its HBV assets (Arbutus 10-K filed in 2017)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top